Cover Image
Read Now

Clinical review report: Dolutegravir/Lamivudine (Dovato) (ViiV Healthcare ULC)

The objective of this systematic review was to evaluate the beneficial and harmful effects of dolutegravir (DTG) 50 mg/lamivudine (3TC) 300 mg administered orally in a fixed-dose combination (FDC) as a complete regimen for the treatment of HIV-1 infection in adults and adolescents 12 years of age an...

Full description

Bibliographic Details
Corporate Author: Canadian Agency for Drugs and Technologies in Health
Format: eBook
Language:English
Published: Ottawa (ON) Canadian Agency for Drugs and Technologies in Health October 2019, 2019
Edition:Version: Final (with redactions)
Series:CADTH common drug review
Subjects:
Canada
Hiv Integrase Inhibitors / Therapeutic Use
Hiv-1 / Drug Effects
Hiv Infections / Drug Therapy
Treatment Outcome
Anti-hiv Agents / Therapeutic Use
Online Access:
Collection: National Center for Biotechnology Information - Collection details see MPG.ReNa
Description
Summary:The objective of this systematic review was to evaluate the beneficial and harmful effects of dolutegravir (DTG) 50 mg/lamivudine (3TC) 300 mg administered orally in a fixed-dose combination (FDC) as a complete regimen for the treatment of HIV-1 infection in adults and adolescents 12 years of age and older who weigh at least 40 kg
Physical Description:1 PDF file (94 pages) illustrations

Similar Items